基本信息
views: 2
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Schwendeman’s long-term research goal is to design highly potent and safe synthetic high-density lipoprotein (HDL) nanomedicines for treatment of atherosclerosis. These 10 nm size particles mimic the natural HDL function of cholesterol removal from arterial plaques and subsequent cholesterol transport to the liver for elimination. Dr. Schwendeman spent 12 years in pharmaceutical industry at Cerenis Therapeutics (Fierce 15 biotech, www.cerenis.com), Pfizer, and Esperion Therapeutics. She was involved in discovery and translation of several HDL therapies to Phase II clinical trials. Her efforts led to development of a kilo-scale recombinant Apolipoprotein A-I process and highly homogeneous and safe HDL particles for the largest-to-date Phase II sHDL clinical trial (>500 patients). She successfully submitted FDA INDs for six different products including nanoparticles, liposome, proteins, peptides and small molecules.
Her current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency, and designing short synthetic peptides that mimic various functions of Apolipoprotein A-I, the main protein component of HDL. Her laboratory has several ongoing translational collaborative projects focused on assessing sHDL utility for treatment of Alzheimer's disease, sepsis, acute lung injury, lupus and diabetic nephropathy. Dr. Schwendeman also explores the utility of these “nature-made” nanoparticles for targeted delivery of chemotherapeutics to SR-BI (HDL-receptor)-expressing tumors as well as for delivery of peptide antigens. Finally, her laboratory is active in developing science-based regulations for testing of complex parenteral products such as nanoparticles, recombinant proteins and microspheres. Research is currently supported by grants from the American Heart Association and the US Food and Drug Administration.
Her current research interests focus on understanding the mechanisms of how phospholipid composition of HDL affects its potency, and designing short synthetic peptides that mimic various functions of Apolipoprotein A-I, the main protein component of HDL. Her laboratory has several ongoing translational collaborative projects focused on assessing sHDL utility for treatment of Alzheimer's disease, sepsis, acute lung injury, lupus and diabetic nephropathy. Dr. Schwendeman also explores the utility of these “nature-made” nanoparticles for targeted delivery of chemotherapeutics to SR-BI (HDL-receptor)-expressing tumors as well as for delivery of peptide antigens. Finally, her laboratory is active in developing science-based regulations for testing of complex parenteral products such as nanoparticles, recombinant proteins and microspheres. Research is currently supported by grants from the American Heart Association and the US Food and Drug Administration.
Research Interests
Papers共 117 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Mats Ljungman,Huibin Yang,Radhika Suhas Hulbatte,Natalie Gratsch, Alan Kelher, John Raupp,Yin Wang, Kristen Hong Dorsey,Troy Halseth,Anna Schwendeman, Philip Palmbos
Cancer Researchno. 6_Supplement (2024): 6569-6569
Nanomedicine (London, England)no. 29 (2024): 2127-2142
ACS nanono. 22 (2024): 13983-13999
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGYno. 5 (2023): 619-623
Troy A Halseth, Adele B Correia,Mark L Schultz,Maria V Fawaz, Esmée Q Kuiper,Preethi Kumaran, Kristen Hong Dorsey,Edward H Schuchman,Andrew P Lieberman,Anna Schwendeman
Nanomedicine : nanotechnology, biology, and medicine (2023): 102705-102705
Molecular pharmaceuticsno. 11 (2023): 5454-5462
CELL REPORTS METHODSno. 4 (2023): 100440-100440
Load More
Author Statistics
#Papers: 115
#Citation: 2925
H-Index: 28
G-Index: 52
Sociability: 8
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn